Company / Revenue
KalVista Pharmaceuticals, Inc. Revenue History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$50.0M
FY2024
5-year range
$50.0M / $50.0M
FY2020-FY2024
Trend
-
vs FY2023
Sector context
#121 of 155
Health Care
What the data says
Revenue changed +294% YoY in FY2024, a notable deviation from the 5-year average annual change of +278%.
Based on SEC 10-K filings.
$50M in FY2024 with a 5-year CAGR of +101.5%.
Improved from $2M to $50M over the past 5 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +101.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 155This company $50.0M Sector average $4.5B
▼
-98.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +101.5%, indicating consistent growth.
- Ranks #121 out of 155 companies in the Health Care sector.
- Lowest revenue in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $50.0M | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | $12.7M | +743.8% |
| FY2019 | $1.5M | -29.5% |
| FY2018 | $2.1M | -74.6% |
| FY2017 | $8.4M | +458.1% |
| FY2016 | $1.5M | -29.5% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026